Kane Interim CEO Dr. Robert Huizinga to present at the Advanced Wound Care Summit USA
Jul 15 – Jul 17, 2025
Investor Relations
Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms.
Upcoming Events
Latest Financial Results
Q1 2025
Quarter Ended Mar 31, 2025
Stock Information
Kane Biotech is also listed on the US OTC under the symbol KNBIF.
Company Overview
Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms.
Investor Contact Information
Company
Kane Biotech Inc.
190-100 Innovation Drive
Winnipeg, MB R3T 6G2
Canada
T: (204) 453-1301
ir@kanebiotech.com
Investor Relations
Kane Biotech Inc.
T: 204-453-1301
ir@kanebiotech.com
Transfer Agent
Canadian Stock Transfer Company Inc.
600, 333 – 7th Avenue S.W.
Calgary, Alberta T2P 2Z1